Business
Press Release Sep 07 2022
Cipla Limited has informed the Exchange about press release dated 07-Sep-2022 titled Cipla receives USFDA approval for the generic version of Revlimid�� (Lenalidomide capsules)
About this update from Cipla Ltd
Cipla Limited has informed the Exchange about press release dated 07-Sep-2022 titled Cipla receives USFDA approval for the generic version of Revlimid�� (Lenalidomide capsules) View Attachment
More from Cipla Ltd
Cipla Announces Exclusive Partnership with Qilu Pharmaceutical for the Licensing and Supply of Biosimilar to Keytruda in the US
September 4, 2026
Cipla Announces Exclusive Partnership with Qilu Pharmaceutical for the Licensing and Supply of Biosimilar to Keytruda® (Pembrolizumab) in...
September 3, 2026